IL240988A - Lactam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions - Google Patents
Lactam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditionsInfo
- Publication number
- IL240988A IL240988A IL240988A IL24098815A IL240988A IL 240988 A IL240988 A IL 240988A IL 240988 A IL240988 A IL 240988A IL 24098815 A IL24098815 A IL 24098815A IL 240988 A IL240988 A IL 240988A
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- treatment
- conditions
- mediated diseases
- selective agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793736P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029057 WO2014144584A2 (en) | 2013-03-15 | 2014-03-14 | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL240988A0 IL240988A0 (en) | 2015-11-30 |
| IL240988A true IL240988A (en) | 2017-05-29 |
Family
ID=50897877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240988A IL240988A (en) | 2013-03-15 | 2015-09-01 | Lactam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions |
| IL250077A IL250077A0 (en) | 2013-03-15 | 2017-01-12 | Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250077A IL250077A0 (en) | 2013-03-15 | 2017-01-12 | Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9688627B2 (enExample) |
| EP (2) | EP3235817B1 (enExample) |
| JP (2) | JP6317807B2 (enExample) |
| KR (1) | KR20150130326A (enExample) |
| CN (1) | CN105143217A (enExample) |
| AU (1) | AU2014228973B2 (enExample) |
| BR (1) | BR112015023080A2 (enExample) |
| CA (1) | CA2906134A1 (enExample) |
| DK (1) | DK2989098T3 (enExample) |
| EA (1) | EA201591793A1 (enExample) |
| ES (1) | ES2635635T3 (enExample) |
| IL (2) | IL240988A (enExample) |
| PH (1) | PH12015502165A1 (enExample) |
| PT (1) | PT2989098T (enExample) |
| SG (1) | SG11201507470WA (enExample) |
| WO (1) | WO2014144584A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2875022B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| CN105392505A (zh) | 2013-07-19 | 2016-03-09 | 开曼化学股份有限公司 | 用于促进骨生长的方法、系统和组合物 |
| CN107365329B (zh) * | 2016-05-12 | 2019-02-01 | 华东师范大学 | 一种3-甲基-2-氧代-5-庚炔基磷酸二甲酯的制备方法 |
| PL3733665T3 (pl) | 2017-12-25 | 2023-02-06 | Asahi Kasei Pharma Corporation | Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| CA1085859A (en) | 1975-06-27 | 1980-09-16 | Wilhelm Bartmann | Pyrrolidones and process for their manufacture |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4268522A (en) | 1976-06-14 | 1981-05-19 | Pfizer Inc. | 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| AP2002002555A0 (en) | 1999-12-22 | 2002-06-30 | Pfizer Prod Inc | EP4 Receptor selective agonists in the treatment of osteoporosis. |
| US20010056060A1 (en) | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| EA200300379A1 (ru) * | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| JP2004521954A (ja) | 2001-07-16 | 2004-07-22 | エフ．ホフマン−ラ ロシュ アーゲー | Ｅｐ４受容体作用薬としてのプロスタグランジン類似体 |
| PL215425B1 (pl) | 2001-07-16 | 2013-12-31 | Ono Pharmaceutical Co | Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie |
| JP4273407B2 (ja) | 2001-07-23 | 2009-06-03 | 小野薬品工業株式会社 | Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤 |
| AU2002340282B2 (en) | 2001-10-23 | 2007-08-09 | Merck Serono Sa | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors |
| WO2003047417A2 (en) | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Ep4 receptor agonist, compositions and methods thereof |
| AU2002346562A1 (en) | 2001-12-03 | 2003-06-17 | Merck & Co., Inc. | Method for treating ocular hypertension |
| AU2003211574A1 (en) | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| ATE336247T1 (de) | 2002-03-18 | 2006-09-15 | Pfizer Prod Inc | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten |
| EP1490055A1 (en) | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2003237520B2 (en) * | 2002-06-10 | 2009-01-08 | Laboratoires Serono Sa | Gamma lactams as prostaglandin agonists and use thereof |
| WO2004037786A2 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
| WO2004065365A1 (ja) | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | ８−アザプロスタグランジン誘導体およびその医薬用途 |
| JP4662926B2 (ja) * | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| EP1782829A1 (en) | 2004-08-10 | 2007-05-09 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| US7858610B2 (en) | 2004-08-10 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
| JP5040650B2 (ja) * | 2005-06-03 | 2012-10-03 | 小野薬品工業株式会社 | 神経再生および／または保護剤 |
| US20070232660A1 (en) | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| CN101686985A (zh) | 2007-05-08 | 2010-03-31 | 国立大学法人浜松医科大学 | 含有ep4激动剂的细胞毒性t细胞的活化剂 |
| EP2215084B1 (en) | 2007-10-23 | 2016-09-28 | Allergan, Inc. | Therapeutic substituted lactams |
| WO2011003058A1 (en) * | 2009-07-03 | 2011-01-06 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
| EP2638008B1 (en) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| US20120283293A1 (en) | 2011-05-06 | 2012-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation |
| US9682065B2 (en) | 2011-08-02 | 2017-06-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
| EP2875022B1 (en) | 2012-07-19 | 2016-10-12 | Cayman Chemical Company, Incorporated | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
-
2014
- 2014-03-14 PT PT147291066T patent/PT2989098T/pt unknown
- 2014-03-14 JP JP2016502973A patent/JP6317807B2/ja active Active
- 2014-03-14 EP EP17169751.9A patent/EP3235817B1/en not_active Not-in-force
- 2014-03-14 BR BR112015023080A patent/BR112015023080A2/pt not_active IP Right Cessation
- 2014-03-14 DK DK14729106.6T patent/DK2989098T3/en active
- 2014-03-14 WO PCT/US2014/029057 patent/WO2014144584A2/en not_active Ceased
- 2014-03-14 SG SG11201507470WA patent/SG11201507470WA/en unknown
- 2014-03-14 AU AU2014228973A patent/AU2014228973B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157026225A patent/KR20150130326A/ko not_active Withdrawn
- 2014-03-14 CA CA2906134A patent/CA2906134A1/en active Pending
- 2014-03-14 CN CN201480015554.7A patent/CN105143217A/zh active Pending
- 2014-03-14 ES ES14729106.6T patent/ES2635635T3/es active Active
- 2014-03-14 US US14/775,427 patent/US9688627B2/en active Active
- 2014-03-14 EP EP14729106.6A patent/EP2989098B1/en active Active
- 2014-03-14 EA EA201591793A patent/EA201591793A1/ru unknown
-
2015
- 2015-09-01 IL IL240988A patent/IL240988A/en active IP Right Grant
- 2015-09-15 PH PH12015502165A patent/PH12015502165A1/en unknown
-
2017
- 2017-01-12 IL IL250077A patent/IL250077A0/en unknown
- 2017-06-01 JP JP2017109178A patent/JP6352497B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6352497B2 (ja) | 2018-07-04 |
| AU2014228973A1 (en) | 2015-09-17 |
| EP2989098B1 (en) | 2017-05-10 |
| EA201591793A1 (ru) | 2016-01-29 |
| CA2906134A1 (en) | 2014-09-18 |
| AU2014228973B2 (en) | 2018-11-08 |
| US20160060216A1 (en) | 2016-03-03 |
| JP2016516050A (ja) | 2016-06-02 |
| US9688627B2 (en) | 2017-06-27 |
| JP6317807B2 (ja) | 2018-04-25 |
| IL240988A0 (en) | 2015-11-30 |
| HK1222170A1 (en) | 2017-06-23 |
| PT2989098T (pt) | 2017-08-16 |
| BR112015023080A2 (pt) | 2017-07-18 |
| WO2014144584A2 (en) | 2014-09-18 |
| EP3235817A1 (en) | 2017-10-25 |
| PH12015502165A1 (en) | 2016-01-25 |
| IL250077A0 (en) | 2017-03-30 |
| CN105143217A (zh) | 2015-12-09 |
| KR20150130326A (ko) | 2015-11-23 |
| EP2989098A2 (en) | 2016-03-02 |
| SG11201507470WA (en) | 2015-10-29 |
| DK2989098T3 (en) | 2017-08-28 |
| WO2014144584A3 (en) | 2014-11-20 |
| JP2017186356A (ja) | 2017-10-12 |
| EP3235817B1 (en) | 2018-12-12 |
| ES2635635T3 (es) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| GB2513167B (en) | Tetrahydrocannabivarin for use in the treatment of nausea and vomiting | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| IL294463B1 (en) | Ocular injectable compounds for use in the treatment of geographic atrophy | |
| IL242610A0 (en) | History of pyrazolopyrrolidine and their use in the treatment of diseases | |
| SG11201601412XA (en) | Compositions and methods for the treatment of presbyopia | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| PT3004108T (pt) | Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças | |
| IL236637A (en) | Diploorulctam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
| SG11201602579SA (en) | Bicyclic alkyne derivatives and uses thereof | |
| IL250077A0 (en) | Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions | |
| ZA201508050B (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| PL2968478T3 (pl) | Kompozycje i sposoby do leczenia karboksyhemoglobinemii | |
| EP2941248A4 (en) | COMPOSITION AND METHOD FOR TREATING BODY SURFACE | |
| HUE036306T2 (hu) | Odiparcil alkalmazása mukopoliszacharidózis kezelésében | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |